Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/rheumatology/keaf677 http://scihub22266oqcxt.onion/10.1093/rheumatology/keaf677 41390925!?!41390925 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=41390925&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Rheumatology+(Oxford) 2025 ; ? (?): ? Nephropedia Template TP {{tp|p=41390925|t=2025. Predictors and long-term impact of sustained complete renal response in lupus nephritis patients over a median 10-year follow-up |pdf=|usr=}}{{41390925}} gab.com Text Predictors and long-term impact of sustained complete renal response in lupus nephritis patients over a median 10-year follow-up JO: Rheumatology (Oxford) http://www.kidney.de/pget.php?&tw=1&pmid=41390925 #FOAvip OBJECTIVES: Complete renal response (CRR) is a primary goal in lupus nephritis (LN) management. We examined the prevalence and predictors of sustained CRR (sCRR), and long-term outcomes. METHODS: We included 142 inception cohort patients with biopsy-proven LN from two academic centres. We assessed the prevalence of sCRR achievement for >/=12 months and the impact of sCRR duration on renal flares, severe kidney function decline (>/=30% eGFR decline compared with baseline), a composite end-stage kidney disease (ESKD) or death outcome, and disease damage. We analyzed data over a median 121-month follow-up, using linear, logistic, and Cox regression models. RESULTS: 83% of patients achieved sCRR for >/=12 months, 56.3% for >/=5 years and 20.4% for >/=10 years. Persistent hydroxychloroquine use (adjusted HR: 1.86, p = 0.004), non-nephrotic baseline proteinuria (adjusted HR: 1.71, p = 0.016) and class III vs class IV LN (HR: 1.89, p = 0.018) were associated with earlier sCRR achievement. The 5- and 10-year post-sCRR risks for renal flares decreased for every additional year on CRR. sCRR duration rather than its mere achievement reduced the risk of >/= 30% eGFR decline (adjusted OR: 0.81/year, p = 0.015) and composite ESKD/death (adjusted HR : 0.75/year, p = 0.001). sCRR >/= 12 months protected against damage accrual (adjusted beta-coef=-1.17, p < 0.001). Among those with >/=100-month follow-up, sCRR >/= 4 years protected against severe kidney function decline (adjusted OR: 0.10, p = 0.005), ESKD/death (adjusted HR: 0.11, p = 0.043) and damage accrual (adjusted beta-coef=-0.81, p = 0.012). CONCLUSION: Persistent hydroxychloroquine, non-nephrotic baseline proteinuria and class III vs IV are associated with earlier sCRR. sCRR >/=4 years protects against >/=30% eGFR decline, composite ESKD/death, and damage. Twit Text FOAVip Predictors and long-term impact of sustained complete renal response in lupus nephritis patients over a median 10-year follow-up ????Rheumatology (Oxford) http://www.kidney.de/pget.php?&tw=1&pmid=41390925 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=41390925 #FOAvip English Wikipedia <ref>{{Cite pmid|41390925}}</ref> Predictors and long-term impact of sustained complete renal response in lupus nephritis patients over a median 10-year follow-up #MMPMID41390925 Michelakis IE; Kapsia E; Boletis JN; Marinaki S; Sfikakis PP; Tektonidou MG Rheumatology (Oxford) 2025[Dec]; ? (?): ? PMID41390925show ga OBJECTIVES: Complete renal response (CRR) is a primary goal in lupus nephritis (LN) management. We examined the prevalence and predictors of sustained CRR (sCRR), and long-term outcomes. METHODS: We included 142 inception cohort patients with biopsy-proven LN from two academic centres. We assessed the prevalence of sCRR achievement for >/=12 months and the impact of sCRR duration on renal flares, severe kidney function decline (>/=30% eGFR decline compared with baseline), a composite end-stage kidney disease (ESKD) or death outcome, and disease damage. We analyzed data over a median 121-month follow-up, using linear, logistic, and Cox regression models. RESULTS: 83% of patients achieved sCRR for >/=12 months, 56.3% for >/=5 years and 20.4% for >/=10 years. Persistent hydroxychloroquine use (adjusted HR: 1.86, p = 0.004), non-nephrotic baseline proteinuria (adjusted HR: 1.71, p = 0.016) and class III vs class IV LN (HR: 1.89, p = 0.018) were associated with earlier sCRR achievement. The 5- and 10-year post-sCRR risks for renal flares decreased for every additional year on CRR. sCRR duration rather than its mere achievement reduced the risk of >/= 30% eGFR decline (adjusted OR: 0.81/year, p = 0.015) and composite ESKD/death (adjusted HR : 0.75/year, p = 0.001). sCRR >/= 12 months protected against damage accrual (adjusted beta-coef=-1.17, p < 0.001). Among those with >/=100-month follow-up, sCRR >/= 4 years protected against severe kidney function decline (adjusted OR: 0.10, p = 0.005), ESKD/death (adjusted HR: 0.11, p = 0.043) and damage accrual (adjusted beta-coef=-0.81, p = 0.012). CONCLUSION: Persistent hydroxychloroquine, non-nephrotic baseline proteinuria and class III vs IV are associated with earlier sCRR. sCRR >/=4 years protects against >/=30% eGFR decline, composite ESKD/death, and damage. ?Predictors and long-term impact of sustained complete renal response i(epmc).pdf DeepDyve Pubget Overpricing